<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 171 from Anon (session_user_id: 83152d35b5e87d3ab1e990885d97986ed6b23067)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 171 from Anon (session_user_id: 83152d35b5e87d3ab1e990885d97986ed6b23067)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value">There is<span> a </span>CpG, union of cytosine with guanine dinucleotides in the DNA. These dinucleotides are found in great quantity in the promoter   regions of the genes(CpG Islands), areas of initiation of transcription of genes. In some cases, the cytosine is methylated.         This methylation can be normal along the DNA, but in CpG Islands areas are normally free of methylation<span>. </span>On<span> the </span>other hand in cancer  cells, the promoter CpG Islands are converted into hipermethylated making the underlying gene silencing. In cancer, the   methylation of CpG Islands inactivates the tumor suppressor gene, this decreases the transcription<span>, </span>and contributes to the   carcinogenia. All mammals are in the areas of repetitive DNA dinucleotides ofhigh density highly methylated and intergenicas have   low density of dinucleotides which are also highly methylated in the regions. Although its function is poorly known certain    intergenicas sequences they have regulatory functions. In the cancer of intergenicas regions and repetitive elements have low methylation. It has been discovered intergenicas sequences are important modulating of the expression of genes of the chromatin and these can be  transcribed, and has emerged a good amount of non-coding genes,                                                                                              non-codingRNA displayed aberrant expression that contributes to several types of cancer, such as leukemia, cancer colorectal, neuroblastomas and hepatocellular carcinomas<span>.</span><br /></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value">Example, cluster H19 / Igf2. We find on the paternal allele, the control of printing region (ICR) this methylated, therefore enhancers can regulate the expression and exert their action at a distance on the gene Igf2, allowing its expression. On the other hand on the maternal allele, control of printing region (ICR) not this methylated , which joins CTCF, this prevents that action on Igf2 enhancers.  this causes the expression of the H19 gene. In tumor Wilms,the control region print (ICR) this hipermethylated , this causes the expression of the Igf2 gene. In the  Wilms tumor, the maternal allele is methylated, and the patern allele the control print region also methylated. This allows that in the case of wilms tumor is expressed only the Igf2 gene. In the case of Wilms tumor when hypermethylation in the control region of printing there is overexposure of genes that promote growth. It is in this case promotes the growth of kidney or wilms tumor.<br /></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value">Decitabine is used to treat myelodysplastic syndromes, forerunners of acutemyelogenous leukemia. <br />Myelodysplastic syndrome is another form of cancer. There is abnormal methylation of genes that regulate and control the growth ofcells in cancer. <br />Decitabine is an agent hipometilizante that interferes with theabnormal methylation. <br />Decitabine decreased methylation in myelodysplastic syndrome. <br />In cancer decitabine lowers the levels of methylation in the tumorsuppressor genes, allowing its expression. Tumor suppressor genes prevent the abnormal growth of cells<span>.</span></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value">            <div><br /></div>Dr  Baylin  speculates  that  their  drugs  can  have  lasting  effects  due  to  the  study  that I  conducted  with  its  working  group .  This  study  found  that  combining  an  inhibitor of  histone  deacetylase-azacitidine affected  the  growth  of  tumor  in  the  lung ,  also  found that  to  deliver  chemotherapeutic  drugs  more  later ,  they  did  a  better  job  than before ,  because  cancer  cells  were  made  is  decreased  more  susceptible  to chemotherapy .  These  drugs  are  involved  in  the  DNA  methylation  allowing  the expression  of  precursor  tumor  genes  by  interfering  with  the  growth  of  cells .  Dr Baylin  assertion  can  be  possible  since  the  epigenetic  changes  can  pass  through  cell division  cell  daughters  permanently  affecting  the  cell. A sensitive period is a period critical that itmay affect permanently the structure and function of the cell and the organism<span>. <br /></span>Sensitive periods can be identified during pregnancy, both the preimplantation prior<span> to </span>the embryonic development, and primordial germ cells are critical periods since these epigenetic marks are determined<span>. </span>Treat patients during sensitive periods   could be unwise since could be affected your condition permanently during his lifetime<span>.</span>  </div>
  </body>
</html>